For almost a decade now, there has been a significant increase in studies related to digestive tract cancer and its treatment, as shown by the different clinical guidelines disseminated at European and global level. For this reason, the development of new drugs and their testing in clinical trials is one of our main lines of research. We also focus on the study and identification of new prognostic and predictive biomarkers of response through the use of liquid biopsy with special interest in the analysis of circulating free tumour DNA (ctDNA) and circulating tumour cells (CTC) for the characterisation of minimal residual disease. We also studied the prognostic and predictive value of using an artificial intelligence-based radiomic model in this group of patients. Finally, the use of organoid models generated from the patient's own tumour cells (or normal tissue) for molecular characterisation of the disease and drug testing is another of our priorities.
At the clinical research level, we conduct clinical trials in order to:
- Validate new drugs or reuse others.
- Demonstrate the predictive value of biomarkers.
- Determine the recommended dose for treatment.
Our group aims to develop new therapeutic interventions to improve the diagnosis and prognosis of patients suffering from cancer related to the digestive system, mainly based on:
- The identification of molecular and imaging biomarkers.
- A better understanding of the carcinogenesis of these tumours.
At the translational research level, we study not only carcinogenesis but also the mechanisms of resistance to treatments and the identification of new biomarkers with the use of techniques that are at the forefront of research such as liquid biopsy (ctDNA, microRNAs or CTCs), high-throughput platforms such as massive next-generation sequencing, radiomics, or the development of preclinical models such as organoids for early diagnosis, monitoring and characterisation of the disease and prediction of prognosis and therapeutic responses in patients with gastrointestinal neoplasms.
Colorectal cancer and new therapeutic developments in solid tumours
Molecular characterisation of colorectal cancer by liquid biopsy based on the analysis of ctDNA and CTCs. Application of radiomics in prognostic assessment. Study of the mechanisms of resistance to standard and targeted therapy and identification of new therapeutic targets. Development of clinical trials with drugs directed against potentially targetable alterations.
- CERVANTES RUIPEREZ, ANDRES MANUEL R
- PDI-Catedratic/a d'Universitat
- ALFARO CERVELLO, CLARA
- Alumn.-Servei de Formacio Permanent
- Secretari/a de Departament
- CASTILLO ALIAGA, JOSEFA
- PDI-Contractat/Da Doctor/A
- Coordinador/a Curs
- ESPI MACIAS, ALEJANDRO
- PDI-Titular d'Universitat
- JIMENEZ MARTI, ELENA
- Alumn.-Servei de Formacio Permanent
- PEREZ FIDALGO, JOSE ALEJANDRO
- PDI-Associat/Da Assistencial Ciencies Salut
Partners
- Inma Blasco Blasco - Fundació per a la Investigació de l'Hospital Clínic de la Comunitat Valenciana
- Valentina Gambardella - Fundació per a la Investigació de l'Hospital Clínic de la Comunitat Valenciana
- Maria del Sol Huerta Alvaro - Universitat de valència
- Amelia Insa Mollá - Hospital Clínic Universitari de València
- Susana Roselló Keränen - Hospital Clínic Universitari de València
Work team
- Tania Fleitas Kanonnikoff - Fundació per a la Investigació de l'Hospital Clínic de la Comunitat Valenciana
- Francisco Gimeno Valiente - Fundació per a la Investigació de l'Hospital Clínic de la Comunitat Valenciana
- Gabriela Pérez Garrity - Fundació per a la Investigació de l'Hospital Clínic de la Comunitat Valenciana
Blasco Ibáñez Campus
Av. Blasco Ibáñez, 15
46010 València (Valencia)
- CERVANTES RUIPEREZ, ANDRES MANUEL R
- PDI-Catedratic/a d'Universitat
